Rare 'manufacturing defect' in GSK vaccine noted by Australian regulators

It appears to be a case of no harm, no foul. A dose of GlaxoSmithKline's ($GSK) Fluarix flu vaccine was found to have a particle of what appeared to be glass blocking the action of the syringe. The discovery of the "manufacturing defect" led regulators in Australia to give providers a heads up to check syringes before giving shots. But they said it was the rarest of events, likely to occur only once in 10 million doses and unlikely to harm a patient if it does. The Therapeutic Goods Administration (TGA) said the vaccine on the market can continue to be used but that providers should check Fluarix pre-filled vaccine syringes for any "foreign particulate matter" before giving a shot. The TGA is investigating further. Release